Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, October 21, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Determining the Value of Waste Materials as Fuel Feedstock
Thursday, March 20, 2014
Model 440 CHN Elemental Analyzer used to determine percentage of CHN in a waste sample.

Optibrium, Integrated Chemistry Design Collaborate on New iPad App
Monday, March 17, 2014
Asteris for iPad enables drug discovery scientists to quickly explore high quality compound ideas.

Double O-ring Ensures High Integrity Cap Mat Seal
Thursday, March 13, 2014
New silicone cap mats from Porvair Sciences.

Xylem’s Bellingham + Stanley Launch High Specification Polarimeters
Wednesday, March 12, 2014
The ADP600 Series are high accuracy Peltier temperature-controlled polarimeters.

Exeter Analytical Launches Entry Level CHN Analyzer
Tuesday, March 04, 2014
Model 440 analyzer determines CHN percentage levels quickly, easily and reliably.

New Release for Cresset’s Drug Discovery Software
Monday, March 03, 2014
The latest set of Pipeline Pilot components V2.0.0, includes new tools for 3D visualization of field patterns, SAR data analysis and 3D-QSAR modeling.

CHN Analyzer for Contract Research Organizations and Service Labs
Friday, February 14, 2014
Model 440 delivers simultaneous CHN analysis in less than 5 minutes.

Biotage Announces the Launch of ISOLUTE® PLD+
Monday, January 27, 2014
Improved sensitivity with the new protein and phospholipid removal plate.

Powerful Evaporator for Drug Discovery
Thursday, January 02, 2014
The HT-4X centrifugal evaporator from Genevac provides optimised sample preparation capabilities for scientists working in the drug discovery environment.

<< 2 3 4 5 6 7 8 >>
Showing Results 41 - 50 of 1271
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv